Principal Investigator: Gregory Zipfel, MD (WUSTL Neurosurgery)
Co-investigators: Robert Mach, PhD (WUSTL Radiology), Byung Hee Han, PhD (WUSTL Neurosurgery)
Cerebral amyloid angiopathy (CAA) is found in approximately one-third of all elderly patients (> 60 years of age) and about 90% of patients with Alzheimer’s Disease (AD). CAA is a well-recognized cause of brain hemorrhage and is also a known contributor to ischemic stroke and dementia. Yet, to date only a “possible” or “probable” diagnosis of CAA is achievable without obtaining brain tissue from the patient via biopsy, or at autopsy.
This project provides a basis for a non-invasive method of diagnosing CAA in live patients, to permit the diagnosis of CAA prior to onset of brain hemorrhage; enable critical studies to be performed to conclusively establish and define the contribution of CAA to Alzheimer’s Disease, other forms of dementia, and ischemic stroke; and greatly facilitate the development of desperately needed clinical trials to test promising new CAA therapies that are currently in the research pipeline.
“PET tracers for cerebrovascular-specific amyloid imaging”
American Health Assistance Foundation Research Award (Han, PI; Zipfel, Co-Investigator)
“Phenoxazine Derivatives and Methods of Use Thereof”; Attorney Docket Number 047563-401187; Inventors: Gregory Zipfel, Henry Han, Robert Mach, Wenhua Chu; Provisional Patent Submitted July 30, 2010. (Patent Pending)